Abstract:The main aim of this study is to synthesize contrast microbubbles (MB) functionalized with engineered protein ligands using a microfluidic device to target breast cancer specific vascular B7-H3 receptor in vivo for diagnostic ultrasound imaging. We used a high-affinity affibody (ABY) selected against human/mouse B7-H3 receptor for engineering targeted MBs (TMBs). We introduced a C-terminal cysteine residue to this ABY ligand for facilitating site-specific conjugation to DSPE-PEG-2K-maleimide (M. Wt = 2.9416 kDa) phospholipid for MB formulation. We optimized the reaction conditions of bioconjugations and applied it for microfluidic based synthesis of TMBs using DSPE-PEG-ABY and DPPC liposomes (5:95 mole %). The binding affinity of TMBs to B7-H3 (MBB7-H3) was tested in vitro in MS1 endothelial cells expressing human B7-H3 (MS1B7-H3) by flow chamber assay, and by ex vivo in the mammary tumors of a transgenic mouse model (FVB/N-Tg (MMTV-PyMT)634Mul/J), expressing murine B7-H3 in the vascular endothelial cells by immunostaining analyses. We successfully optimized the conditions needed for generating TMBs using a microfluidic system. The synthesized MBs showed higher affinity to MS1 cells engineered to express higher level of hB7-H3, and in the endothelial cells of mouse tumor tissue upon injecting TMBs in a live animal. The average number (mean ± SD) of MBB7-H3 binding to MS1B7-H3 cells was estimated to be 354.4 ± 52.3 per field of view (FOV) compared to wild-type control cells (MS1WT; 36.2 ± 7.5/FOV). The non-targeted MBs did not show any selective binding affinity to both the cells (37.7 ± 7.8/FOV for MS1B7-H3 and 28.3 ± 6.7/FOV for MS1WT cells). The fluorescently labeled MBB7-H3 upon systemic injection in vivo co-localized to tumor vessels, expressing B7-H3 receptor, as validated by ex vivo immunofluorescence analyses. We have successfully synthesized a novel MBB7-H3 via microfluidic device, which allows us to produce on demand TMBs for clinical applications. This clinically translatable MBB7-H3 showed significant binding affinity to vascular endothelial cells expressing B7-H3 both in vitro and in vivo, which shows its potential for clinical translation as a molecular ultrasound contrast agent for human applications.

Lyp-1 Ultrasonic Microbubbles Targeting To Cancer Cell As Tumor Bio-Acoustics Markers Or Drug Carriers: Targeting Efficiency Evaluation In Microfluidic Channels

Microbubbles Conjoining LyP-1 as a Tumor Probe for Ultrasound Molecular Imaging: Targeting Efficiency Evaluation on Microfluidic Platform

Preparation and Antitumor Activity of Bfgf-Mediated Active Targeting Doxorubicin Microbubbles

Introduction of Ultrasound Microbubble Technology Aided Tumor Imaging and Treatment

The Optimized Fabrication of a Novel Nanobubble for Tumor Imaging

Ultrasound-mediated targeted microbubbles: a new vehicle for cancer therapy

A Novel Microfluidic Chip for Assessing Dynamic Adhesion Behavior of Cell-Targeting Microbubbles

Multifunctionalized Microbubbles for Cancer Diagnosis and Therapy

Ultrasensitive Optical Detection and Elimination of Residual Microtumors with a Postoperative Implantable Hydrogel Sensor for Preventing Cancer Recurrence.

Therapeutic Ultrasonic Microbubbles Carrying Paclitaxel and LyP-1 Peptide: Preparation, Characterization and Application to Ultrasound-Assisted Chemotherapy in Breast Cancer Cells

Nano/Microparticles And Ultrasound Contrast Agents

Advances in low-frequency ultrasound combined with microbubbles in targeted tumor therapy

Therapeutic ultrasound microbubbles carrying paclitaxel and LyP-1 peptide: Preparation, characterization and application to ultrasonic assisted chemotherapy in breast cancer cells

Preparation of Nanoscale Molecular Targeting Ultrasound Contrast Agents and Its Tumor Targeting Experiment in Vitro

Size-Modulable Nanoprobe for High-Performance Ultrasound Imaging and Drug Delivery against Cancer

Evaluation of a Targeted Nanobubble Ultrasound Contrast Agent for Potential Tumor Imaging

Targeting nanoparticle-conjugated microbubbles combined with ultrasound-mediated microbubble destruction for enhanced tumor therapy

Preparation of Ultrasound Contrast Agent Microbubbles Combining Anti-MUC 1 Monoclone Antibody and Evaluation of Targeting Capability in Vitro

Combined Legumain- and Integrin-Targeted Nanobubbles for Molecular Ultrasound Imaging of Breast Cancer.

Preparation of Lipid Nano-Bubbles as Contrast Agent Material for Tumor Ultrasound Diagnosis of Breast Cancer

Synthesis and Evaluation of Clinically Translatable Targeted Microbubbles Using a Microfluidic Device for In Vivo Ultrasound Molecular Imaging